European Commission Approves SPEVIGO® (spesolimab) for Generalized Pustular Psoriasis (GPP) Flares

Boehringer Ingelheim’s spesolimab was granted conditional marketing authorization from the European Commission (EC) to treat generalized pustular psoriasis (GPP) flares in adults. Spesolimab is a selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP. This conditional approval is based on Phase II clinical trial results for EFFISAYIL® 1. Carinne Brouillon, Member of the Board of Managing Directors responsible for Human Pharma, Boehringer Ingelheim stated, “We are delighted to be able to bring this much needed treatment to patients with GPP, whose options were incredibly limited until this year. This approval marks another significant milestone in the continued development of spesolimab in neutrophilic skin diseases, which we are investigating in further clinical trials.”Boehringer Ingelheim’s spesolimab was granted conditional marketing authorization from the European Commission (EC) to treat generalized pustular psoriasis (GPP) flares in adults. Spesolimab is a selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP. This conditional approval is based on Phase II clinical trial results for EFFISAYIL® 1. Carinne Brouillon, Member of the Board of Managing Directors responsible for Human Pharma, Boehringer Ingelheim stated, “We are delighted to be able to bring this much needed treatment to patients with GPP, whose options were incredibly limited until this year. This approval marks another significant milestone in the continued development of spesolimab in neutrophilic skin diseases, which we are investigating in further clinical trials.”